Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects

• Published in: Respiratory research Vol. 23; no. 1; pp. 1 - 9
• Main Authors: Maher, Toby M., Bourdin, Arnaud, Volkmann, Elizabeth R., Vettori, Serena, Distler, Jörg H. W., Alves, Margarida, Stock, Christian, Distler, Oliver
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05.07.2022; BioMed Central; BMC
• Subjects: Age; Connective tissue diseases; Development and progression; Diagnosis; Dyspnea; Ethnicity; Human health and pathology; Humans; Life Sciences; Lung; Lung diseases; Lung Diseases, Interstitial; Minority & ethnic groups; Patient outcomes; Placebos; Pulmonary fibrosis; Pulmonology and respiratory tract; Respiratory function; Risk factors; Santé publique et épidémiologie; Scleroderma; Scleroderma (Disease); Scleroderma, Systemic; Sex; Systemic scleroderma; Systemic sclerosis; Vital Capacity; United States; systemic; Vital capacity; Pulmonary fibrosis; Scleroderma; Connective tissue diseases
• ISSN: 1465-993X; 1465-9921; 1465-993X
• DOI: 10.1186/s12931-022-02095-6

Background The forced vital capacity (FVC) of healthy individuals depends on their age, sex, ethnicity and height. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is characterised by loss of FVC. We compared FVC values in the subjects with SSc-ILD in the SENSCIS trial of nintedanib...